Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating ...

B 2026 tracking litigation highlights drugmaker mandates and legal challenges reshaping hospital drug pricing and compliance risks.

Eli Lilly and Company said Monday evening that it will soon end 340B discount pricing for some of the hospitals that have not ...

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

Amistad Community Health Center CEO Dr. Eric Baggerman says rising prescription costs are making access to medication more difficult for many patients.

Three hospitals have sued CVS Health alleging the company redirected $250 million in savings from the 340B program. Mount Sinai Hospital, including St. Luke's-Roosevelt Hospital and Mount Sinai Beth ...

Eli Lilly gives hospitals 5 days to submit claims data or lose access to discounted 340B drug pricing, enforcing new transparency rules.

This appeal concerns Maine's effort to use state law to impose additional obligations on drug manufacturers who participate ...

Two recent federal court cases signal new significant developments with respect to the 340B Drug Pricing Program. Specifically: (1) new federal district court litigation challenging a recent HRSA ...

Although 340B does not operate through the tax code, its economic effects mirror those of a tax expenditure. Recognizing it as such would not prejudge the program’s merits but would force a ...